WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006083214) PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A HMG-COA REDUCTASE INHIBITOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/083214    International Application No.:    PCT/SE2006/000136
Publication Date: 10.08.2006 International Filing Date: 31.01.2006
IPC:
A61K 31/505 (2006.01), A61K 31/165 (2006.01), A61K 31/351 (2006.01), A61K 31/402 (2006.01), A61K 31/405 (2006.01), A61K 31/435 (2006.01), A61K 31/44 (2006.01), A61K 31/495 (2006.01), A61P 9/10 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (For All Designated States Except US).
BOUGHTON-SMITH, Nigel [GB/GB]; (GB) (For US Only).
BRADDOCK, Martin [GB/GB]; (GB) (For US Only)
Inventors: BOUGHTON-SMITH, Nigel; (GB).
BRADDOCK, Martin; (GB)
Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE)
Priority Data:
0500258-9 02.02.2005 SE
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A HMG-COA REDUCTASE INHIBITOR
(FR) COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTAGONISTE DU RECEPTEUR P2X7 ET UN INHIBITEUR DE HMG-COA REDUCTASE
Abstract: front page image
(EN)The invention provides a pharmaceutical composition, product or kit comprising a first active ingredient which is a P2X7 receptor antagonist and a second active ingredient which is a HMG-CoA reductase inhibitor. The P2X7 receptor antagonist is optionally an adamantly derivate and the HMG-CoA reductase inhibitor a statin. The invention is intended for use in the treatment of cardiovascular disorders, especially atherosclerosis.
(FR)L'invention concerne une composition pharmaceutique, un produit ou une trousse comprenant un premier ingrédient actif qui est un antagoniste du récepteur P2X7 et un second ingrédient actif qui est un inhibiteur de HMG-CoA réductase. L'antagoniste du récepteur P2X7 est éventuellement constamment un dérivé et l'inhibiteur de HMG-CoA réductase une statine. L'invention concerne l'utilisation de cette composition dans le traitement de troubles cardio-vasculaires, notamment l'athérosclérose.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)